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Abstract 
OBJECTIVE: To perform a randomized, placebo-controlled, double-blind study, with a 
follow-up period of 6 months, for the use of topical clobetasol in cases of symptomatic 
oral lichen planus (OLP).  
SUBJECTS AND METHODS: Thirty-two participants were analyzed, with the aims of: (I) 
to compare the usefulness of topically applied clobetasol propionate 0.05% (mixed with 
4% hydroxyethyl cellulose gel) and 4% hydroxyethyl cellulose gel alone (considered as 
placebo) in the management of OLP; (II) to describe which of them is quicker in 
decreasing signs and reported symptoms, and (III) which is able to give the proper longer 
remission in the follow-up.  
RESULTS: Symptoms improved in all clobetasol treated patients during the first 2 months 
of therapy, while only 50% of placebo control group (P=0.005) displayed similar results; of 
the remaining half, 12.5% did experienced a worsening whilst 37.5% remained stable. 
Regarding clinical signs, 87.5% of clobetasol treated patients improved, while only 62.5% 
of the placebo treated patients had a positive response (P=0.229).  
CONCLUSIONS: It is possible to report that clobetasol, at this dosage, has been more 
effective than a placebo at provoking symptoms improvement in subjects affected by 
atrophic erosive oral lesions. 
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Introduction 
Oral lichen planus (OLP) is a chronic inflammatory disease, affecting almost 2% of the 
total population; female subjects are involved about more than twice than males. Patients 
of all ages could be affected, generally during the fifth or the sixth decades of life (Carbone 
et al, 2009b; Arduino et al, 2013; Baccaglini et al, 2013). To date, the specific etiology 
remains undetermined; immune dysregulation has been described to play a critical part, 
possibly, with the disease being the outcome of the influence of a large range of extrinsic 
antigens or altered self-antigens (Carbone et al, 2009a; Mustafa et al, 2015). Occasionally, 
precipitating aspects have been reported, including dental materials, medications, stressful 
events, traumatic agents, and some infectious agents (Carbone et al, 2009a; Baccaglini et 
al, 2013).  
Two main clinical forms of OLP have been detailed: white lesions (WL) are mostly 
asymptomatic, while atrophic and erosive lesions (RL) could result in intense discomfort 
(Carbone et al, 2009a). It was supposed that those different clinical types may be 
characterized by dissimilar cells and biological events (Janardhanam et al, 2012); 
moreover, the considerable reported accumulation of CD3, CD4, CD8 and CD56 
lymphocytes in the lesion, together with the consequent cell mediated immunological 
mechanisms, could determine the evolving of OLP into RL manifestation, with a marked 
tissue damage; otherwise, WL are usually characterized by less tissue damage (Lorenzini 
et al, 2013), and this response could be induced by different immune-mediated pathways. 
Suggested therapies are typically symptomatic with numerous medication used, but 
recently, it has been published that there is unsatisfactory evidence to support the success 
of any specific treatment as being more reliable than another (Lodi et al, 2012). 
Management of symptomatic OLP is commonly empirical, although topical steroids are 
considered first line treatment, with no adequate control groups or corrected study designs 
(Carrozzo and Gandolfo, 1999; Zakrzewska et al, 2005; Arduino et al, 2013).  
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In this sense, clobetasol propionate appeared to be one of the most effective topical 
steroids, as in an adhesive base led to complete remission in 56-75% of patients with 
symptomatic OLP (Conrotto et al, 2006; Carbone et al, 2009a – 2009b; Lodi et al, 2012; 
Arduino et al, 2013). 
To the best of our knowledge, a randomized-controlled evaluation of the efficacy of 
topically applied clobetasol versus placebo in the treatment of atrophic-erosive OLP is still 
lacking. Consequently, our aims were: (I) to compare the usefulness of topically applied 
clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel) and 4% 
hydroxyethyl cellulose gel alone (considered as placebo) in the management of OLP in a 
double-blind-randomized protocol, (II) to resolve which of them is quicker in decreasing 
signs and reported symptoms and (III) to determine which is able to give the proper 
remission in the follow-up.  
The current trial is written according to the CONSORT statement for improving the quality 
of reports of randomised controlled trials (http://www.consort-statement.org/). 
 
Subjects and method 
Protocol proposal 
An eight-week randomized-double-blind controlled trial was planned. Local ethical 
committee approval was achieved before starting and all participants were given a written 
informed consent; the present trial has been registered with ISRCTN (#10647973). The 
research was conducted in accordance with ethical principles stated in the World Medical 
Association Declaration of Helsinki. 
Our study was split in two stages: during stage I, participants underwent topical treatment 
for 8 consecutive weeks, while stage II consisted of a treatment-free follow-up of six 
months. 
 6 
Computer-generated randomization lists and allocation sequences were prepared by an 
independent statistician not involved in the study. Two blocks were created: for 
participants 1–20 and 20–50. Consequent allocation was ensured by keeping the 
randomization lists in the care of one of the investigators (R.B.), not involved in the clinical 
part of the study. The medicines were distributed in identical plastic containers, packed by 
an external pharmacist unaware of the protocol. The coded tubes were consecutively 
numbered according to the randomization list.  
Subjects were divided into two groups: the first one received clobetasol propionate 0.05% 
cream mixed with a 4% hydroxyethyl cellulose adhesive gel, whereas the second received 
only the latter.  
During treatment, neither the principal investigator (M.C.) nor the involved subjects knew 
which one of the two treatments they were using. 
  
Participants 
Consecutive individuals, attending the Oral Medicine Section of the Department of Surgical 
Sciences, CIR-Dental School (Turin, Italy), were enrolled, and considered eligible if having 
a histological diagnosis of OLP, on the basis of WHO criteria (Kramer et al,1978), and 
presenting painful lesions. Participants were not admitted if any of the succeeding 
exclusion conditions were reported: occurrence dysplasia in the histopathological 
specimen; use of lichenoid reaction inducing medication and presence of amalgam fillings 
nearby the lesions; interventions for OLP in the previous 12 weeks; pregnant or 
breastfeeding women; proved or suspected hypersensitivity to any of the chemicals used 
in the treatment (Arduino et al, 2013). 
 
 Topical formulations 
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1st arm: clobetasol propionate was melted in 95% alcohol with a soluble additive (Abil 
8851). Hydroxyethyl cellulose was melted in boiled water and slowly turned. At the 
temperature of 30° C, the 4% hydroxyethyl cellulose gel was then mixed with an equivalent 
amount of previously melted clobetasol propionate, in order to obtain a final concentration 
containing 0.05% of the steroid (Carbone et al, 2009b). 
2nd arm: 4% hydroxyethyl cellulose gel prepared as above, and then packed separately.  
 
Intervention 
The medications had to be applied twice a day for 8 consecutive weeks; for the final 
evaluation, we included patients with less than three missed medication doses during the 
entire treatment period, provided they were not consecutive (Carbone et al, 2009b; 
Arduino et al, 2013): finger rub application on dried lesions after meals without eating, 
drinking or speaking for at least half an hour afterwards. Anti-mycotic treatment was added 
to the therapy of both groups as prophylaxis against possible oropharyngeal candidosis, 
consisting of miconazole gel (Micotef®, LPB, Cinisello B., Milano, Italy) plus 0.12% 
chlorhexidine mouth rinse (Plack-out®, BYK, Gulden Italia, Cormano, Milano, Italy), once 
and twice daily respectively (Carbone et al, 2009b). 
 
Assessment 
Patient were assessed through a detailed recollection of anamnestic data and oral 
symptoms, followed by a conventional oral examination and photographic documentation 
of the lesions observed by a single physician (M.C.). This clinic-anamnestic method was 
done every two weeks during the protocol period, and twice during the follow-up.  
The clinical data were detailed according to certain criteria (Thongprasom et al, 1992): 
score 0: no lesions; score 1: hyperkeratotic lesions; score 2: atrophic area £ 1 cm²; score 
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3: atrophic area > 1 cm²; score 4: erosive area £  1 cm²; score 5: erosive area > 1 cm²; 
resolution of the clinical signs was described as before (Arduino et al, 2013).  
Symptoms were measured using a visual analogue scale (VAS), as detailed in previous 
works (Conrotto et al, 2006; Arduino et al, 2013).  
After the end of the protocol, the stability of the obtained results was assessed in two 
different times: the first after 8 weeks and the second after 24 weeks. The differences 
between the two groups, when present, were also evaluated. In this period, if any subject 
still complained symptoms or reported new ones, they would start the usual treatment, 
comprehensive of clobetasol propionate 0.05% mixed with 4% hydroxyethyl cellulose, as 
previously reported (Carbone et al, 2009b). 
 
Statistical analysis 
The sample size was calculated according to available data suggesting an overall efficacy 
of 70% and 20% for topically applied clobetasol and hydroxyetil cellulose, respectively. 
With a power of 85% and a type I error of 0.05, 32 patients (16 for each arm) were 
needed.  
We described quantitative (continuous) variables using medians and first and third 
quartiles (Q1 and Q3); for qualitative (categorical) data, we used frequencies and 
percentages. The non-normality of the distributions of continuous variables were verified 
via Kolmogorov-Smirnov tests, so differences between medians were tested using 
Kruskal-Wallis tests. Fisher’s exact tests were performed to evaluate differences in 
categorical variables.  
All statistical analyses were performed using SAS-ver.9.3 (SAS Institute Inc.), and a 2-tails 
p-value less than 0.05 was considered statistically significant. 
 
Results 
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Forty-Three Caucasian patients were screened. Four of them refused, while three did not 
meet our requirements and had to be excluded, with two of them being already under 
treatment with lichenoid reaction inducing drugs and one showing histological signs of 
dysplasia.  
Fig. 1 reports the flow diagram for patients’ recruitment.  
Participants’ characteristics are described in Table 1. Thirty-Six patients (30 women, 6 
men, mean age 66.28) joined our study. At baseline, participants in the clobetasol group 
reported a median VAS of 4.00 (Q1 = 3.00; Q3 = 5.75), quite similar to that reported by 
subjects in the placebo group which was of 4.50 (Q1 = 3.00; Q3 = 7.00), with no statistical 
difference. The described score was instead worse in clobetasol group [median value of 
4.00 (Q1 = 4.00; Q3 = 5.00)] when compared with that of the placebo group [median value 
of 4.00 (Q1 = 4.00; Q3 = 4.00)], being this difference statistical significant (Table 1).  
In the first four weeks, two patients recruited in the clobetasol group dropped out for 
personal reasons, whereas two placebo patients gave up for uncontrolled continued pain. 
The remaining 32 patients were able to complete the protocol and were finally analyzed. 
Table 2 describes the comparison of reported symptoms and described scores between 
the two groups (considering the continuous variables), during the different steps of the 
proposed protocol. It is worth noting that clobetasol seemed to be able to improve 
symptoms and signs when compared to placebo in every step of our protocol (P<0.05), 
except when comparing baseline data to those obtained after four weeks of treatment in 
terms of reported pain (P=0.237). 
When considering results in terms of improvement and not in terms of continuous data, 
results are similar. After 4 weeks of treatment, 87.5% of the subjects in the clobetasol arm 
reported less pain in comparison of 40% of placebo arm, showing a faster activity for the 
steroid (P=0.005, with Fisher’s exact test). After 8 weeks, symptoms improved in all 
patients treated with clobetasol (100%) during the first two months of treatment; on the 
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other hand, only 50% of controls undergoing therapy with placebo showed similar results 
(P=0.005, with Fisher’s exact test) while the remaining half reported either a worsening 
(12.5%) or no change at all (37.5%).  
Regarding clinical signs, 87.5% of clobetasol treated patients improved after 2 months of 
therapy, while only 62.5% of the placebo treated patients had a positive response (defined 
as the disappearance of all atrophic-erosive lesions, regardless of any persisting 
hyperkeratotic lesions); however, the difference was not statistically significant (P=0.229, 
Fisher’s exact test).  
At the end of the first eight weeks, some adverse effects were noticed; in the clobetasol 
group, one patient experienced episodes of gastroesophageal reflux and in the placebo 
group one reported a severe skin erythematous reaction (possibly due to the antimitotic 
medication), both enough severe to require discontinuation of therapy. Moreover, one 
patient in the clobetasol group described a mild increase in the fasting blood sugar level, 
but he was able to complete the study. There were no statistically significant differences 
between the two groups regarding the incidence of adverse reactions (P>0.05, Fisher’s 
exact test). 
We also assessed the reported compliance (e.g. number of missed application) without 
any difference between the two groups (data not showed). None of the enrolled subjects 
had specific trouble in applying the medications. 
During the 24 weeks of the follow up period, six participants (37%), previously treated in 
the clobetasol arm, needed to be retreated due to new symptomatic oral lesions, while the 
remaining 10 did not experience new lesions or symptoms. At the same time, eight 
patients treated (50%) in the placebo arm need to be treated with the standard topical 
steroid therapy because of enduring symptoms. This difference was not statistically 
significant (P>0.05%), neither if considering the medium amount of time after the end of 
the protocol (22 weeks in the clobetasol arm, and 20 weeks in the placebo one). 
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Discussion 
To the best of our knowledge, this is the first randomized, double-blind and controlled 
study ever reported attempting to assess efficacy of a specific topical corticosteroid (e.g. 
clobetasol propionate 0.05%) versus placebo in the topical treatment of oral erosive OLP.  
Clobetasol belongs to US Class I (Europe: class IV) of the corticosteroids, making it one of 
the most potent accessible. It is offered via a large range of classes including shampoo, 
mousse, ointment and emollient cream. 
As previously reported by our own group either with topical steroids (Conrotto et al, 2006; 
Carbone et al, 2009b), or with other immunosuppressant agents (Conrotto et al, 2006; 
Arduino et al, 2013), we added the hydroxyethylcellulose to clobetasol, in order to make 
the application better attachable to the oral mucosa, and used it on its own as placebo.  
Erosive OLP affecting mucosal surfaces is frequently sorer and more debilitating than the 
non-erosive forms. Its management is problematic and aimed at palliation rather than cure; 
numerous topical and systemic agents have been used with different outcomes (Cheng et 
al, 2012). At present, the treatment most commonly suggested by oral medicine physicians 
involves the use of corticosteroids.  
In fact, topical steroids are usually considered a first-line therapy for many muco-
cutaneous inflammatory conditions, being more efficient when used to treat superficial 
inflammation involving the epidermis, upper dermis, or dermal-epidermal junction. Topical 
steroid application might be superior to systemic corticosteroids for treating such 
conditions (Wilken et al, 2015). 
Commonly used topical steroids include clobetasol propionate (0.025 - 0.05%), 
fluocinonide (0.025 - 0.05%), triamcinolone acetonide (0.05 - 0.5%), and, less frequently, 
fluticasone propionate or betamethasone sodium phosphate (Gupta et al, 2017). 
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Clobetasol has been widely reported to be effective in the treatment of OLP lesions 
through its prevention of inflammatory processes such as oedema, fibrin deposition, 
vasodilation, and phagocytic activity (Chamani et al, 2015). Furthermore, according to a 
very recent systematic review, topical application of 0.025 or 0.05% clobetasol propionate 
should be considered the first therapeutic option in the management of erosive OLP 
(Garcia-Pola et al, 2017; Gupta et al, 2017). 
To date, only two studies performed a comparative analysis between clobetasol and 
placebo; our own group firstly reported this difference in a non-randomized manner, 
showing enhancement among 90% of OLP patients treated with clobetasol, whereas in the 
placebo group only 20% of subjects displayed improvement (Carbone et al, 1999). More 
recently, Brazilian Authors tried to establish a similar comparison among 22 patients with 
OLP-related desquamative gingivitis, finding that within the period designed to treat the 
gingival lesions, clobetasol propionate did not significantly outperform the placebo (Motta 
et al, 2009). However, the brief amount of time destined to treatment with such medication 
– only three consecutive weeks, with only one administration a day in the third week – as 
well as the potential protection of gingival tissues offered by trays, may have contributed to 
such discordance in respect to our previous results. 
In the present study, clobetasol, at the aforementioned posology, has been more effective 
than a placebo in inducing clinical improvement amid patients affected by atrophic erosive 
lesions. Even though clinical signs did not show the same pattern of improvement, it is 
important to remember that frequently there is no positive correlation between the severity 
of the oral clinical pattern detectable at conventional oral examination, and the reported 
pain: in our clinical experience, patients with larger lesions sometimes complain less than 
those who deal with small but very painful lesions. 
One of the limitation of the analysis is the decision to use the Thongprasom’s score for the 
clinical assessment; this score has not been validated, differently from COMDQ for 
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example (Riordain et al, 2016), but however it has been largely used especially by our 
group in previous manuscripts (Thongprasom et al, 1992; Carbone et al, 1999; Conrotto et 
al, 2006; Arduino et al, 2014), being simply and well reproducible.   
As OLP tends to relapse commonly after treatment termination, long-lasting properties and 
effects of used medications have to be considered carefully.  
During follow-up, we observed that clobetasol participants were more stable than placebo 
ones, with a superior constancy of the therapeutic efficiency during the subsequent drug-
free six months. Unfortunately, the usefulness of clobetasol in the long-lasting period is still 
poor and many patients needed to be retreated. 
Concerning this matter, one study showed significant side effects after the administration 
of topical steroids in ulcerative and erosive lesions (Gonzalez-Moles et al, 2002). 
However, our twenty-year clinical experience in regards to the administration of propionate 
clobetasol in 4% hydroxyethyl cellulose, allows us to state with enough confidence that 
such treatment can be considered safe, with side-effects usually limited to oral candidosis, 
which can be prevented through the association with topical antifungal agent and 
chlorhexidine-based mouthwash. In this report only one steroid treated patients (6.25%) 
had to stop the medication due to abdominal pain, but this type of side effects has never 
been reported in medical literature, and so could be defined as a very rare occurrence 
(less than 1 case for 10.000 treated patients); the mild hypergylcemia reported from 
another patient has been already described as side-effect, but usually occurring after 
prolonged application and high percutaneous absorption, so probably it would be difficult 
to explain only with topical intraoral application for 1 month (Coondoo et al, 2014). 
Of course, we agree with the consensus among Authors that patients under this type of 
treatment should be supervised cautiously (Plemons et al, 1990; Voûte et al, 1993; Motta 
et al, 2009). 
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In conclusion, the 4% hydroxyethyl cellulose gel mixed with an equivalent amount of 
previously melted clobetasol propionate to obtain a finishing concentrations containing 
0.05% of the drug, should be possibly considered as first line of treatment for erosive and 
ulcerative lesions in OLP patients, considering that the therapeutic outcome is mainly due 
to its corticosteroid component. 
Because of the relatively small sample size, further studies with larger groups of patients 
and controls are needed in order to assess the reproducibility of these preliminary results.   
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Figure 1 Flow of subjects through each phase. 
 
 
